[--[65.84.65.76]--]
SYNGENE
SYNGENE INTERNATIONAL LTD

730.75 -13.75 (-1.85%)

Related News for SYNGENE

Positive Breakout: Syngene International and 2 other stocks cross above their 200 DMA

 12 Feb 08:20 AM

For more such web stories click on the ET

F&O stocks to buy today: Trent, Apollo Tyre among top 9 trading ideas for 31 January 2024

 31 Jan 09:30 AM

Positive setup was seen in stocks like Syngene, HPCL, BHEL, LIC Housing Finance, Bosch Ltd, DLF, Tata Motors, BPCL, PNB, MGL, Manappuram Finance, Bank of Baroda, Birla Soft, HAL and Zydus Life.

No change in 30% EBITDA margin guidance or long-term investment plan: Jonathan Hunt, Syngene

 29 Jan 10:36 AM

Syngene International, led by Jonathan Hunt, MD & CEO, remains committed to its long-term investment plans despite a guidance cut. The company experienced a slight softness in Q3 but expects it to be a temporary trend in the US biotech segment due to a slowdown in funding. The EBITDA margin guidance of around 30% remains unchanged, and the company is confident in its strong margin structure. As for capex guidance, the company adjusted it to $60 million for the year, with $40 million already invested and $20 million to be completed in the current quarter.

Syngene Intl Consolidated December 2023 Net Sales at Rs 853.50 crore, up 8.6% Y-o-Y

 29 Jan 10:22 AM

NULL

Syngene Intl Standalone December 2023 Net Sales at Rs 791.90 crore, up 0.67% Y-o-Y

 29 Jan 09:44 AM

NULL

Syngene International Q3 Results: Net profit rises 2% YoY to Rs 112 crore, company revises revenue guidance

 25 Jan 07:43 PM

The rise in Q3 profit of Syngene International was led by dedicated centres and development and manufacturing services, even as discovery services business remained soft. The third quarter revenue from operations rose 9% YoY to Rs. 854 crore. The earnings before interest, tax, depreciation and ammortisation (EBITDA) rose 5% YoY to Rs. 261 crore in Q3FY24. The EBITDA margin dropped 100 basis points YoY to 30%.

SYNGENE INTERNATIONAL: CO SAYS BIOTECH SECTOR FACES SLOWDOWN IN US FUNDING, LEADING TO ADJUSTED REVENUE GROWTH PROJECTIONS IN NEAR TERM

 25 Jan 02:47 PM

SYNGENE INTERNATIONAL: CO SAYS BIOTECH SECTOR FACES SLOWDOWN IN US FUNDING, LEADING TO ADJUSTED REVENUE GROWTH PROJECTIONS IN NEAR TERM

SYNGENE INTERNATIONAL: Q3 EBITDA 2.3B RUPEES VS 2.3B (YOY) || Q3 EBITDA MARGIN 27.12% VS 29.39% (YOY)

 25 Jan 02:33 PM

SYNGENE INTERNATIONAL: Q3 EBITDA 2.3B RUPEES VS 2.3B (YOY) || Q3 EBITDA MARGIN 27.12% VS 29.39% (YOY)

SYNGENE INTERNATIONAL: Q3 REVENUE 8.53B RUPEES VS 7.86B (YOY)

 25 Jan 02:32 PM

SYNGENE INTERNATIONAL: Q3 REVENUE 8.53B RUPEES VS 7.86B (YOY)

SYNGENE INTERNATIONAL: Q3 CONS NET PROFIT 1.1B RUPEES VS 1.09B (YOY)

 25 Jan 02:32 PM

SYNGENE INTERNATIONAL: Q3 CONS NET PROFIT 1.1B RUPEES VS 1.09B (YOY)